Crossmark

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials

Crossref DOI link: https://doi.org/10.1007/s00259-021-05348-6

Published Online: 2021-04-29

Published Print: 2021-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kaddu-Mulindwa, Dominic https://orcid.org/0000-0001-8832-252X
Altmann, Bettina

Held, Gerhard

Angel, Stephanie

Stilgenbauer, Stephan

Thurner, Lorenz

Bewarder, Moritz

Schwier, Maren

Pfreundschuh, Michael

Löffler, Markus

Menhart, Karin

Grosse, Jirka

Ziepert, Marita

Herrmann, Ken

Dührsen, Ulrich

Hüttmann, Andreas

Barbato, Francesco

Poeschel, Viola

Hellwig, Dirk https://orcid.org/0000-0002-3056-0143
Funding

Funding for this research was provided by:

Deutsche Krebshilfe (107592, 110515)

F. Hoffmann-La Roche

Roche

Amgen

Acrotech Biopharma LLC
License Information

Text and Data Mining valid from 2021-04-29

Version of Record valid from 2021-04-29
More Information

Article History

Received: 3 January 2021

Accepted: 29 March 2021

First Online: 29 April 2021

Declarations

:

: Both trials were approved by the Federal Institute for Drugs and Medical Devices and the ethics committees of the participating centers. All patients gave written informed consent.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below